Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He’ll Make ‘Every Time’
Hims & Hers Health (HIMS) cut its 2026 profit outlook for the third time this year, reporting a $33M quarterly loss despite a 49% revenue increase. Subscribers fell 100,000 due to strategic marketing adjustments. CEO Andrew Dudum defended the decisions, emphasizing long-term growth. The stock dropped 12% during the day and another 2-3% after hours, now 44% below its year-ago level.
How this was made
The 30-second read
Why it matters
The latest 8‑K guidance cut and quarterly loss represent the first public disclosure of the new profit outlook, prompting immediate price weakness.
Market read
Fresh guidance downgrade and loss drive a sharp sell‑off in HIMS, with potential spill‑over to the broader health‑tech sector.
What to watch
Subscriber base grew 13% YoY and the upcoming addition of Zepbound and Foundayo could improve margins later in 2026.
Background
Hims & Hers Health (NYSE:HIMS) provides telehealth and consumer‑health products, recently expanding into weight‑loss and peptide therapies.
Ticker impact
Hims & Hers Health cut its 2026 adjusted EBITDA guidance to $257‑$277 million, down 21% from February, and reported a $33 million quarterly loss.
likely further downside as investors price in weaker profit outlook
The company reduced its profit plan for the third time this year and posted a loss, prompting a 12% drop in regular trading and additional after‑hours weakness.
Market effects
Weight‑loss and telehealth peers may see heightened scrutiny as Hims & Hers signals weaker demand and tighter marketing spend.
U.S. biotech and consumer‑health stocks could face short‑term pressure amid the guidance downgrade.
Limited to investors tracking U.S. health‑tech equities; no broader macro impact.
Counterpoint
The company still holds $710 million of cash and may use the capital to fund new product launches, offering a potential upside if the market overreacts to the guidance cut.
Key entities
- CEOAndrew Dudum
Chief executive who framed the subscriber losses as a strategic trade.
- Board MemberAndrew Huberman
New director hired to promote the Peptides+ launch.
